Subcision Followed by Diluted Calcium Hydroxylapatite Injection Versus Subcision Followed by Painting CROSS TCA Technique for the Treatment of Atrophic Acne Scars

NCT07028567 | Completed

• 1 other identifier: 36195/12/22
• Study Type: interventional
• Target: 13
• Locations: 1 country
• Sites: 1

Brief Summary

This study aimed to compare the safety and efficacy of subcision followed by diluted calcium hydroxyapatite injection versus subcision followed by the painting original chemical reconstruction of skin scars (CROSS) technique using trichloroacetic acid (TCA) for the treatment of atrophic acne scars.

Conditions

Subcision; Calcium Hydroxylapatite; Trichloroacetic Acid; Atrophic Acne Scar

Outcome Measures

Primary Outcomes (1)

• Patient satisfaction

  Patient satisfaction was assessed at the final follow-up visit using a 5-point Likert-type scale, comparing outcomes to the pre-treatment condition. The scale ranged from 1 (highly dissatisfied), 2 (slightly dissatisfied), 3 (neither satisfied nor dissatisfied), 4 (satisfied), to 5 (highly satisfied).

  One week

Study Arms (1)

Study group

EXPERIMENTAL

Patients with atrophic acne scars.

Drug: Calcium hydroxylapatite filler; Drug: Painting chemical reconstruction of skin scars trichloroacetic acid technique

Interventions

Calcium hydroxylapatite filler DRUG

Patients received calcium hydroxylapatite filler (CaHA) (Radiesse®).

Study group

Painting chemical reconstruction of skin scars trichloroacetic acid technique DRUG

Patients received painting chemical reconstruction of skin scars (CROSS) trichloroacetic acid (TCA) technique.

Study group

Eligibility Criteria

• Age: 20 Years - 50 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Age from 20 to 50 years.
• Both sexes.
• Patients with atrophic acne scars.

You may not qualify if:

• Patients with Fitzpatrick skin phototypes V and VI.
• Receiving systemic isotretinoin medication at the time of the study.
• Active bacterial, viral or fungal infections in the treatment area.
• Hypertrophic scarring or keloidal tendency.
• Photosensitivity or photodermatitis.
• Unrealistic expectation, bleeding, coagulation disorders, and any other related skin disease.
• Pregnant or lactating females.
• Chronic debilitating diseases such as diabetes mellitus, cardiovascular diseases, renal failure, hepatic diseases, chronic respiratory diseases or any endocrine diseases.
• History of immunosuppressive drug intake or chemotherapy within 6 months before treatment.

Sponsors & Collaborators

• Tanta University: lead

Study Sites (1)

Tanta University

Tanta, El-Gharbia, 31527, Egypt

Location

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Resident of Dermatology and Venereology, Faculty of Medicine, Tanta University, Tanta, Egypt.

Study Record Dates

• First Submitted: June 11, 2025
• First Posted: June 19, 2025
• Study Start: January 1, 2023
• Primary Completion: June 22, 2023
• Study Completion: June 22, 2023
• Last Updated: June 19, 2025

Record last verified: 2025-06

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL
• Time Frame: After the end of study for one year.
• Access Criteria: The data will be available upon a reasonable request from the corresponding author.

Locations

EG (1)